1. Home
  2. IMUX vs CODA Comparison

IMUX vs CODA Comparison

Compare IMUX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • CODA
  • Stock Information
  • Founded
  • IMUX 2016
  • CODA 1994
  • Country
  • IMUX United States
  • CODA United States
  • Employees
  • IMUX N/A
  • CODA N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • CODA Industrial Machinery/Components
  • Sector
  • IMUX Health Care
  • CODA Industrials
  • Exchange
  • IMUX Nasdaq
  • CODA Nasdaq
  • Market Cap
  • IMUX 100.0M
  • CODA 89.7M
  • IPO Year
  • IMUX N/A
  • CODA N/A
  • Fundamental
  • Price
  • IMUX $0.95
  • CODA $8.14
  • Analyst Decision
  • IMUX Strong Buy
  • CODA Strong Buy
  • Analyst Count
  • IMUX 6
  • CODA 1
  • Target Price
  • IMUX $12.67
  • CODA $11.00
  • AVG Volume (30 Days)
  • IMUX 991.0K
  • CODA 30.2K
  • Earning Date
  • IMUX 02-20-2025
  • CODA 01-29-2025
  • Dividend Yield
  • IMUX N/A
  • CODA N/A
  • EPS Growth
  • IMUX N/A
  • CODA N/A
  • EPS
  • IMUX N/A
  • CODA 0.26
  • Revenue
  • IMUX N/A
  • CODA $18,824,676.00
  • Revenue This Year
  • IMUX N/A
  • CODA $8.20
  • Revenue Next Year
  • IMUX N/A
  • CODA $18.67
  • P/E Ratio
  • IMUX N/A
  • CODA $31.23
  • Revenue Growth
  • IMUX N/A
  • CODA N/A
  • 52 Week Low
  • IMUX $0.95
  • CODA $5.21
  • 52 Week High
  • IMUX $2.11
  • CODA $9.89
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 36.31
  • CODA 44.17
  • Support Level
  • IMUX $0.99
  • CODA $8.25
  • Resistance Level
  • IMUX $1.05
  • CODA $9.00
  • Average True Range (ATR)
  • IMUX 0.07
  • CODA 0.43
  • MACD
  • IMUX -0.00
  • CODA 0.04
  • Stochastic Oscillator
  • IMUX 1.50
  • CODA 30.62

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About CODA Coda Octopus Group Inc. Common stock

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.

Share on Social Networks: